Avian polynucleotide vaccine formula

Abstract

The avian vaccine formula comprises at least three polynucleotide vaccine valencies each comprising a plasmid integrating, so as to express it in vivo in the host cells, a gene with one avian pathogen valency, these valencies being selected from the group consisting of Marek's disease virus, Newcastle disease virus, infectious bursal disease virus, infectious bronchitis virus, infectious anaemia virus, the plasmids comprising, for each valency, one or more of the genes selected from the group consisting of gB and gD for the Marek's disease virus, HN and F for the Newcastle disease virus, VP2 for the infectious bursal disease virus, S, M and N for the infectious bronchitis virus, C+NS1 for the infectious anaemia virus.

1 . Avian vaccine formula, comprising at least three polynucleotide vaccine valencies each comprising a plasmid integrating, so as to express it in vivo in the host cells, a gene with one avian pathogen valency, these valencies being selected from the group consisting of Marek's disease virus, Newcastle disease virus, infectious bursal disease virus, infectious anaemia virus, the plasmids comprising, for each valency, one or more of the genes selected from the group consisting of gB and gD for the Marek's disease virus, HN and F for the Newcastle disease virus, VP2 for the infectious bursal disease virus, C+NS1 for the infectious anaemia virus.  
     
     
         2 . Vaccine formula according to  claim 1 , wherein, for the valency of the Marek's disease virus, it comprises the gB gene alone.  
     
     
         3 . Formula according to  claim 1 , which comprises the Newcastle disease virus HN and F genes in the same plasmid or in different plasmids.  
     
     
         4 . Vaccine formula according to  claim 1 , wherein the plasmid for the infectious anaemia virus comprises C+NS1 in the same plasmid.  
     
     
         5 . Vaccine formula according to any one of  claims 1  to  4 , which comprises, in addition, at least one valency selected from the group consisting of infectious bronchitis virus, infectious laryngotracheitis virus, encephalomyelitis virus, pneumovirosis virus, and avian plague virus, the plasmids comprising, for these valencies, one or more of the genes selected from the group consisting of S, M and N for the infectious bronchitis virus, gB and gD for the infectious laryngotracheitis virus, env and gag/pro for the encephalomyelitis virus, F and G for the pneumovirosis virus and HA, N and NP for the avian plague virus.  
     
     
         6 . Vaccine formula according to  claim 5 , wherein for the infectious bronchitis virus valency, it comprises the S gene alone.  
     
     
         7 . Vaccine formula according to  claim 5 , wherein for the laryngotracheitis valency, the formula comprises the gB gene alone.  
     
     
         8 . Vaccine formula according to  claim 5 , wherein for the pneumovirosis valency, the formula comprises the two F and G genes in different plasmids or in one and the same plasmid.  
     
     
         9 . Vaccine formula according to  claim 5 , wherein, for the avian plague valency, the formula comprises the HA gene alone.  
     
     
         10 . Vaccine formula according to  claim 5 , wherein for the encephalomyelitis valency, the vaccine formula comprises the env gene.  
     
     
         11 . Vaccine formula according to any one of  claims 1  to  10 , which comprises from 10 ng to 1 mg, preferably from 100 ng to 500 μg, still more preferably from 0.1 μg to 50 μg of each plasmid.  
     
     
         12 . Use of one or more plasmids as described in any one of  claims 1  to  11 , for the manufacture of an avian vaccine intended to vaccinate animals first vaccinated by means of a first vaccine selected from the group consisting of a live whole vaccine, an inactivated whole vaccine, a subunit vaccine, a recombinant vaccine, this first vaccine having the antigen(s) encoded by the plasmid(s) or antigen(s) providing cross-protection.  
     
     
         13 . Vaccination kit grouping together a vaccine formula according to any one of  claims 1  to  11 , and an avian vaccine selected from the group consisting of a live whole vaccine, an inactivated whole vaccine, a subunit vaccine, a recombinant vaccine, this first vaccine having the antigen encoded by the polynucleotide vaccine or an antigen providing cross-protection, for an administration of the latter in first vaccination or as booster with the vaccine formula.  
     
     
         14 . Vaccine formula according to any one of  claims 1  to  11 , accompanied by a leaflet indicating that this formula can be used as booster for a first avian vaccine selected from the group consisting of a live whole vaccine, an inactivated whole vaccine, a subunit vaccine, a recombinant vaccine, this first vaccine having the antigen encoded by the polynucleotide vaccine or an antigen providing cross-protection.